Radiomics scores that could predict the infiltration of tumor-infiltrating CD8+ T cells were developed (AUC: training set 0.75, 95% [CI] 0.66–0.85; validation set 0.71, 95% [CI] 0.55–0.86) [32], which might be useful in identifying potential people with HCC who can benefit from immunotherapies, although the score should be further validated in large-scale prospective cohorts. The gene discussed is CD8A; the disease is neoplasm.